Journal
NATURE REVIEWS IMMUNOLOGY
Volume 9, Issue 5, Pages 353-363Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nri2545
Keywords
-
Categories
Funding
- Ligue Nationale contre le Cancer
- European Union
- Fondation pour la Recherche Medicale, Cancerop le Ile-de-France
- Institut National du Cancer
- Agence Nationale pour la Recherche
- National Institutes of Health (NIH) [EY06765, EY15570]
- Department of Ophthalmology and Visual Sciences [EY02687]
- Foundation for Fighting Blindness (Owings Mills, Maryland, USA)
- Research to Prevent Blindness (New York, USA)
- Macular Vision Research Foundation (West Conshohocken, Pennsylvania, USA)
- American Lebanese and Syrian Associated Charities
- NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER
- NATIONAL EYE INSTITUTE [F32EY006765, P30EY002687, R01EY006765, R01EY015570] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047891, R01AI044828, R01AI040646] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM052735] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The immune system is routinely exposed to dead cells during normal cell turnover, injury and infection. Mechanisms must exist to discriminate between different forms of cell death to correctly eliminate pathogens and promote healing while avoiding responses to self, which can result in autoimmunity. However, an effective immune response against host tissue is often needed to eliminate tumours following treatment with chemotherapeutic agents that trigger tumour cell death. Consequently, a central problem in immunology is to understand how the immune system determines whether cell death is immunogenic, tolerogenic or 'silent'.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available